CDK6 and ovarian carcinoma: Studies have indicated that SNHG17 is upregulated in ovarian cancer and acts as a molecular sponge for miR-214-3p, relieving miR-214-3p’s inhibitory effect on the cell cycle regulator CDK6, thereby promoting the growth of ovarian cancer cells (44).